Background {#Sec1}
==========

The long-term treatment of rheumatoid arthritis (RA) often involves a sequence of different therapies. Patients who have not responded to conventional synthetic disease-modifying anti-rheumatic drugs (DMARDs) have been routinely treated with a tumor necrosis factor inhibitor (TNFi); however, approximately 20 % of patients discontinue TNFi therapy within 12 months due to inefficacy or adverse events (AEs) \[[@CR1], [@CR2]\]. Management of patients who have not responded to treatment with one TNFi may involve switching to another TNFi or an agent with an alternative mechanism of action. Several randomized controlled trials have demonstrated the efficacy of agents with a different mechanism of action versus placebo in patients with an inadequate response to a TNFi \[[@CR3]--[@CR5]\]. In clinical practice, patients receiving a TNFi, such as adalimumab (ADA), may need or choose to switch to an agent with an alternative mechanism of action; an understanding of the impact of switching without an extended washout period is needed.

Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA \[[@CR6]\]. The tofacitinib phase 3 program included six randomized, controlled studies in which tofacitinib was assessed in adult patients with active moderate to severe RA \[[@CR7]--[@CR12]\] as monotherapy or combined with conventional synthetic DMARDs. A 12-month, double-blind, randomized, controlled trial, conducted in 115 centers worldwide, compared the safety and efficacy of tofacitinib 5 or 10 mg twice daily (BID) or ADA 40 mg every 2 weeks (Q2W) with placebo in patients with active RA taking background methotrexate (MTX; 7.5 to 25 mg weekly), who had an inadequate response to MTX (defined as sufficient residual disease activity to meet entry criteria). The primary safety and efficacy data have been reported previously \[[@CR10]\]. Eligible patients who had participated in this blinded study could be enrolled in an open-label extension where they received tofacitinib 10 mg BID (with or without background MTX), regardless of their treatment in the blinded study \[[@CR13]\].

The objective of the current analyses was to describe the safety and efficacy of open-label tofacitinib in an extension study, following a direct switch from blinded treatment with either ADA or tofacitinib for the treatment of moderate to severe RA. The group of patients who received blinded tofacitinib followed by open-label tofacitinib in the extension study could act as a control for such an assessment by representing potential changes to the clinical profile introduced by transition from the double-blind to the open-label study with minimal changes in treatment (dose adjustments permitted for concomitant RA medications and tofacitinib in the extension study).

Methods {#Sec2}
=======

Study design and treatment {#Sec3}
--------------------------

ORAL Standard (A3921064; NCT00853385) was a double-blind, phase 3 trial \[[@CR10]\] in which patients were randomly assigned to one of five regimens, all with stable background MTX: tofacitinib 5 mg BID, tofacitinib 10 mg BID, ADA 40 mg Q2W (subcutaneous injection), placebo for 3 or 6 months followed by tofacitinib 5 mg BID, and placebo for 3 or 6 months followed by tofacitinib 10 mg BID for a total of 12 months.

ORAL Sequel (A3921024; NCT00413699) is an open-label long-term extension study \[[@CR13]\] in which all patients from ORAL Standard were eligible to receive tofacitinib 10 mg BID with or without conventional synthetic DMARDs. Exclusion criteria included treatment-related serious AEs and serious or recurrent infections (including serious or recurrent herpes zoster) in the index study. Patients with latent tuberculosis were allowed to continue in the extension study if they had received an adequate course of therapy. Patients from certain countries (e.g., Korea, Croatia, Denmark, Czech Republic, Germany, Spain, Sweden, Ireland and the United Kingdom) who enrolled in the extension study ≥14 days after their final index study visit were excluded if their absolute lymphocyte count (ALC) values were \<750 cells/mm^3^. Patients from the remaining countries were excluded if their ALC values were \<500 cells/mm^3^.

The current post-hoc analyses included patients who were randomized at baseline to treatment with blinded ADA 40 mg Q2W + MTX or blinded tofacitinib 10 mg BID + MTX in ORAL Standard and subsequently received open-label tofacitinib 10 mg BID (with or without MTX) in the extension study. Although the patients initiated treatment in the long-term extension with tofacitinib 10 mg BID, this could be reduced to 5 mg BID for safety reasons. Additionally, dose adjustments, including tapering and discontinuation (DC) of permitted concomitant RA medications (such as MTX, prednisone and non-steroidal anti-inflammatory drugs) were allowed in response to inadequate efficacy, disease improvement, or for safety reasons.

Each study was performed in compliance with the Declaration of Helsinki and Good Clinical Practice Guidelines established by the International Conference on Harmonization. The final protocols, amendments, and informed consent documentation were reviewed and approved by the institutional review board and the independent ethics committee of each investigational center (Additional file [1](#MOESM1){ref-type="media"}: Table S1).

Patients {#Sec4}
--------

Patients in this analysis included those who were initially enrolled in the phase 3, ORAL Standard study \[[@CR10]\] and subsequently elected to enroll in the extension study \[[@CR13]\]. Eligible patients in the phase 3 study were ≥18 years of age and had received a diagnosis of active RA, as classified according to the American College of Rheumatology (ACR) 1987 Revised Criteria \[[@CR14]\] and had not failed or had an AE to a TNFi in the past. Additional inclusion and exclusion criteria have been described previously \[[@CR10]\]. Patients who completed participation in the study or discontinued for reasons other than treatment-related serious AEs and who met other inclusion/exclusion criteria were invited to enroll in the long-term extension \[[@CR13]\]. For patients enrolling in the long-term extension study within 2 weeks of their last dose in the blinded study, baseline values were obtained from the blinded study.

Statistical analyses {#Sec5}
--------------------

Post-hoc descriptive statistics are reported (data cutoff date 19 April 2012). As the extension study is ongoing, the study database has not yet been locked (i.e., some values may change for the final, locked study database).

### Safety and tolerability assessments {#Sec6}

The incidence of treatment-emergent AEs (TEAEs) was calculated at scheduled visits of the blinded study (baseline, and months 1, 3, 6, 9, and 12) and extension study (baseline, months 1, 2, 3, and every 3 months thereafter).

In the current analyses, the incidence of TEAEs was compared during the last 3 months of blinded therapy and the first 3 months of open-label treatment.

Exposure-adjusted incidence rates (and corresponding 95 % confidence intervals) of DCs due to AEs, serious AEs and serious infections per 100 patient-years from baseline were calculated for patients who completed treatment with ADA 40 mg Q2W + MTX or tofacitinib 10 mg BID + MTX in the blinded study for patients, (1) regardless of whether they entered the extension study, and (2) who then enrolled in the extension study. These analyses were performed for 3-month (months 0 − 3, 3 − 6, 6 − 9, and 9 − 12) and 12-month (months 0 − 12) periods for both the blinded study and the first 12 months of the extension study. Of note, there were two study visits in the last 3 months of the blinded study (visits 5 and 6 at months 9 and 12, respectively), and four study visits in the first 3 months of the extension study (visits 1 − 4, for baseline and months 1, 2, and 3).

### Efficacy assessments {#Sec7}

The following efficacy parameters were measured in patients who completed treatment with ADA + MTX or tofacitinib 10 mg + MTX in the blinded study (or discontinued for reasons other than a treatment-related serious AE) and then switched to the tofacitinib 10 mg group in the extension study: ACR response rates (20 %, 50 %, and 70 % improvement), mean change in Health Assessment Questionnaire-Disability Index (HAQ-DI) scores from the baseline of the blinded study, and Disease Activity Score for 28-joint counts based on the erythrocyte sedimentation rate (DAS28-4(ESR)) \<2.6 response rates at: (1) month 9 (visit 5) of the blinded study ("-3 months" relative to the switch); (2) the time of switching from the blinded to the extension study ("switch"), and (3) month 3 (visit 4) of the extensions study ("+3 months") allowing visit windows of ±1.5 months to capture all efficacy and safety data.

Results {#Sec8}
=======

Patient disposition and demographics {#Sec9}
------------------------------------

Of 204 patients randomized to ADA 40 mg Q2W + MTX in the blinded study, 107 switched to open-label tofacitinib 10 mg BID (105 (98 %) with MTX on day 1) within 2 weeks after their last dose of ADA. Of 201 patients randomized to blinded tofacitinib 10 mg BID + MTX in the blinded study, 126 switched to open-label tofacitinib 10 mg BID (123 (98 %) with MTX on day 1) within 2 weeks. Patient demographic and baseline characteristics were similar across sequences and between those patients who were randomized to ADA 40 mg Q2W + MTX or tofacitinib 10 mg BID + MTX in the blinded study and those who then received tofacitinib 10 mg BID (with or without MTX) in the extension study (Table [1](#Tab1){ref-type="table"}).Table 1Baseline characteristics for patients randomized to double-blind adalimumab (ADA) 40 mg every 2 weeks or tofacitinib 10 mg twice daily (BID) in the phase 3 study \[[@CR10]\] and for the subgroup who then received open-label tofacitinib 10 mg BID in the extension study \[[@CR13]\]Double-blind studyDouble-blind to open-label extension^a^ADA 40 mgTofacitinib 10 mgADA to tofacitinibTofacitinib to tofacitinibn = 204n = 201n = 107n = 126Female, n (%)162 (79.4)168 (83.6)83 (77.6)107 (84.9)White, n (%)148 (72.5)143 (71.1)90 (84.1)98 (77.8)Age in years, mean ± SD52.5 ± 11.752.9 ± 11.852.2 ± 11.451.6 ± 11.2Region of origin, % North America25.524.916.820.6 South America2.91.54.71.6 Europe53.955.760.759.5 Rest of world17.617.917.818.3Tender and swollen joints, mean Tender26.726.128.025.6 Swollen16.415.816.816.1Mean HAQ-DI score1.51.51.51.5Mean DAS28-4(ESR)6.46.56.46.4Mean CRP (mg/L)17.517.316.217.9Positive for rheumatoid factor, %68.266.266.465.9Positive for anti-CCP, %74.864.074.865.1Prior therapy, n (%) TNF inhibitor16 (7.8)14 (7.0)12 (11.2)10 (7.9) Non-TNF inhibitor biologic agent3 (1.5)4 (2.0)1 (0.9)3 (2.4) Disease-modifying drug other than MTX114 (55.9)115 (57.2)66 (61.7)80 (63.5)Concomitant therapy, n (%) Glucocorticoids125 (61.3)129 (64.2)63 (58.9)77 (61.1) Lipid-lowering medication10 (4.9)10 (5.0)6 (5.6)6 (4.8)^a^Baseline values at the start of the double-blind study; includes patients who completed treatment with ADA 40 mg every 2 weeks or tofacitinib 10 mg BID in the blinded study (or discontinued treatment for reasons other than a tofacitinib-related serious adverse event (AE)) and then enrolled in the extension study and switched treatment with minimal washout (≤2 weeks after their last dose of study drug in the blinded study). *CCP* cyclic citrullinated peptide, *CRP* C-reactive protein, *DAS28-4(ESR)* Disease Activity Score for 28-joint counts based on the erythrocyte sedimentation rate, *HAQ-DI* Health Assessment Questionnaire-Disability Index, *MTX* methotrexate, *RA* rheumatoid arthritis, *SD* standard deviation, *TNF* tumor necrosis factor

Safety and tolerability {#Sec10}
-----------------------

On analysis of the proportions of patients with TEAEs occurring 3 months prior to and 3 months after the switch, there was no clear pattern of changes in either the ADA to tofacitinib group or the blinded to open-label tofacitinib group (Table [2](#Tab2){ref-type="table"}). Incidence rates per 100 patient-years of DCs due to AEs, serious AEs, and serious infections over 3-month and 12-month periods were similar in the year before and in the year after switching in both groups (Table [3](#Tab3){ref-type="table"}). Incidence rates were increased in the first 3 months of the extension study (0 − 3 months) compared with the last 3 months of the blinded study (9 − 12 months) for both groups.Table 2Incidence of treatment-emergent adverse events (TEAEs), and the most commonly reported TEAEs (occurring in ≥2 % of patients in any group) during the last 3 months of the double-blind phase 3 study \[[@CR10]\] and the first 3 months of the open-label extension \[[@CR13]\]ADA to tofacitinibTofacitinib to tofacitinibn = 107n = 126−3 months to switch (ADA)Switch to +3 months (tofacitinib)−3 months to switch (tofacitinib)Switch to +3 months (tofacitinib)Safety summaryNumber of patients (%)DCs due to AEs03 (2.8)1 (0.8)3 (2.4)Serious AEs1 (0.9)8 (7.5)4 (3.2)8 (6.3)Serious infections02 (1.9)1 (0.8)2 (1.6)Deaths02 (1.9)^a^00Most commonly reported TEAEsNumber of patients (%)Abdominal pain upper01 (0.9)4 (3.2)1 (0.8)Arthralgia01 (0.9)4 (3.2)2 (1.6)Bronchitis4 (3.7)3 (2.8)6 (4.8)2 (1.6)Cough01 (0.9)1 (0.8)3 (2.4)Depression01 (0.9)3 (2.4)1 (0.8)Fall1 (0.9)1 (0.9)3 (2.4)1 (0.8)Hemoglobin decreased03 (2.8)01 (0.8)Headache02 (1.9)02 (1.6)Nasopharyngitis2 (1.9)4 (3.7)5 (4.0)3 (2.4)Nausea1 (0.9)3 (2.8)1 (0.8)1 (0.8)Edema peripheral1 (0.9)02 (1.6)3 (2.4)Oropharyngeal pain0003 (2.4)Upper respiratory tract infection3 (2.8)5 (4.7)3 (2.4)6 (4.8)Urinary tract infection05 (4.7)2 (1.6)0Vomiting02 (1.9)1 (0.8)0Worsening RA003 (2.4)2 (1.6)Includes patients who completed treatment with adalimumab (ADA) 40 mg every 2 weeks or tofacitinib 10 mg twice daily in the blinded study (or discontinued treatment for reasons other than a tofacitinib-related serious adverse event (AE)) and then enrolled in the extension study and switched treatment with minimal washout (≤2 weeks after their last dose of study drug in the blinded study). ^a^One patient committed suicide 1 day after the first tofacitinib dose in the extension study (it is unknown whether the patient took the study drug on this day). One patient died due to lung malignancy. *DC* discontinuation, *RA* rheumatoid arthritisTable 3Adverse events and change from baseline in selected laboratory variables during the phase 3 double-blind study \[[@CR10]\] and the open-label extension study \[[@CR13]\]Double-blind study^a^Open-label extension study^b^IR per 100 patient-years (95 % CI)0 − 3 months3 − 6 months6 − 9 months9 − 12 monthsTotal 12 months0 − 3 months3 − 6 months6 − 9 months9 − 12 monthsTotal 12 monthsADA 40 mg Q2W (blinded study) to tofacitinib 10 mg BID (extension study)ADA 40 mg Q2WTofacitinib 10 mg BIDN = 204N = 187N = 177N = 163N = 204N = 145N = 130N = 124N = 121N = 145DCs due to AEs16.3 (9.0, 29.5)19.2 (9.6, 38.4)6.7 (2.1, 20.7)4.1 (0.6, 29.3)12.9 (8.6, 19.4)10.0 (4.2, 24.0)9.6 (3.1, 29.9)3.3 (0.5, 23.6)12.0 (3.9, 37.2)8.8 (5.0, 15.6)Serious AEs8.9 (4.0, 19.9)16.8 (8.0, 35.2)6.7 (2.2, 20.7)8.2 (2.1, 32.9)10.3 (6.5, 16.3)16.1 (8.0, 32.2)16.2 (6.8, 39.0)6.7 (1.7, 26.7)8.0 (2.0, 31.8)13.0 (8.1, 20.9)Serious infections04.8 (1.2, 19.1)2.2 (0.3, 15.8)01.7 (0.5, 5.2)4.0 (1.0, 15.9)03.3 (0.5, 23.7)4.0 (0.6, 28.1)2.9 (1.1, 7.9)Tofacitinib 10 mg BID (blinded study) to tofacitinib 10 mg BID (extension study)Tofacitinib 10 mg BIDTofacitinib 10 mg BIDN = 201N = 184N = 173N = 157N = 201N = 146N = 128N = 122N = 109N = 146DCs due to AEs16.7 (9.3, 30.2)22.2 (11.6, 42.7)6.8 (2.2, 21.1)0.0 (0.0, 0.0)13.3 (8.8, 20.0)13.9 (6.6, 29.1)3.3 (0.5, 23.2)10.5 (3.4, 32.5)4.4 (0.6, 31.5)9.1 (5.2, 16.0)Serious AEs20.1 (11.6, 34.5)12.3 (5.1, 29.6)9.1 (3.4, 24.2)8.7 (2.2, 34.8)13.7 (9.1, 20.6)18.0 (9.4, 34.6)9.9 (3.2, 30.6)14.0 (5.3, 37.3)4.4 (0.6, 31.5)13.4 (8.3, 21.5)Serious infections4.6 (1.5, 14.2)2.4 (0.3, 17.3)4.5 (1.1, 18.1)4.3 (0.6, 30.7)4.0 (1.9, 8.4)5.9 (1.9, 18.4)3.3 (0.5, 23.2)3.5 (0.5, 24.8)4.4 (0.6, 31.5)4.5 (2.0, 10.1)Double-blind study^b^Long-term extension study^b^Mean change from baseline (SD)Month 1Month 3Month 6Month 9Month 12Month 1Month 3Month 6Month 9Month 12ADA 40 mg Q2W (blinded study) to tofacitinib 10 mg BID (extension study)ADA 40 mg Q2WTofacitinib 10 mg BIDN = 142N = 142N = 141N = 138N = 132N = 132N = 126N = 118N = 118N = 110Absolute lymphocyte count, cells/mm^3^0.4 (0.6)0.4 (0.6)0.4 (0.6)0.4 (0.6)0.4 (0.7)0.5 (0.8)0.2 (0.6)0.0 (0.6)-0.0 (0.6)-0.0 (0.6)N = 142N = 144N = 144N = 140N = 137N = 139N = 131N = 125N = 122N = 115Total cholesterol, mg/dL8.3 (26.4)6.7 (30.1)2.8 (29.4)-0.1 (29.7)3.2 (33.9)22.8 (33.2)24.5 (38.2)18.9 (36.4)20.8 (35.6)18.8 (37.7)N = 140N = 141N = 142N = 139N = 134N = 1N = 3N = 121N = 2N = 107LDL, mg/dL3.2 (20.5)2.5 (24.9)0.5 (24.3)-3.5 (23.1)-1.8 (27.0)18.9 (N/A)-6.2 (57.8)6.2 (30.2)36.0 (25.5)8.6 (31.9)N = 142N = 144N = 143N = 140N = 135N = 1N = 3N = 122N = 2N = 108HDL, mg/dL3.3 (9.2)3.4 (10.0)1.6 (11.3)3.3 (11.5)5.6 (10.5)20.9 (N/A)13.1 (24.5)11.9 (11.8)10.5 (30.4)8.8 (12.3)N = 142N = 144N = 143N = 140N = 135N = 1N = 5N = 122N = 3N = 108Triglycerides, mg/dL7.8 (49.9)2.8 (41.2)2.7 (45.8)-0.1 (58.7)-6.0 (48.9)5.3 (N/A)2.0 (53.2)4.7 (57.1)8.0 (13.6)3.1 (54.8)Tofacitinib 10 mg BID (blinded study) to tofacitinib 10 mg BID (extension study)Tofacitinib 10 mg BIDTofacitinib 10 mg BIDN = 142N = 141N = 141N = 138N = 129N = 134N = 131N = 116N = 112N = 103Absolute lymphocyte count, cells/mm^3^0.2 (0.5)-0.0 (0.5)-0.1 (0.6)-0.1 (0.6)-0.3(0.6)-0.1 (0.6)-0.2 (0.6)-0.3 (0.6)-0.3 (0.6)-0.3 (0.6)N = 145N = 142N = 141N = 136N = 131N = 136N = 134N = 122N = 117N = 106Total cholesterol, mg/dL28.7 (29.2)27.4 (31.7)30.0 (34.3)29.3 (36.6)32.8 (37.2)30.6 (33.9)27.6 (38.8)22.5 (42.2)23.7 (36.3)29.7 (32.7)N = 141N = 139N = 137N = 133N = 123N = 0N = 5N = 117N = 4N = 100LDL, mg/dL18.7 (25.6)19.1 (25.5)20.7 (31.0)19.8 (31.1)20.0 (31.8)N/A9.8(28.4)13.1 (35.8)16.3(42.5)20.7 (30.7)N = 145N = 142N = 141N = 136N = 127N = 0N = 5N = 121N = 4N = 103HDL, mg/dL8.0 (12.4)6.1 (14.1)7.7 (17.9)7.1 (15.4)8.2 (15.7)N/A16.1 (19.0)8.6 (19.1)7.9 (3.9)9.0 (15.2)N = 145N = 142N = 141N = 136N = 127N = 0N = 7N = 121N = 4N = 103Triglycerides, mg/dL9.2 (65.0)8.4 (69.4)13.0 (87.3)12.3 (91.0)15.0 (83.3)N/A25.5 (69.2)12.9 (84.8)6.6 (61.7)7.5 (70.1)^**a**^Includes patients who were treated with adalimumab (ADA) 40 mg every 2 weeks (Q2W) or tofacitinib 10 mg twice daily (BID) from baseline in the blinded study, regardless of whether they entered the extension study. ^**b**^Includes all patients who completed treatment with ADA 40 mg Q2W or tofacitinib 10 mg BID in the blinded study and then switched treatment and completed 12 months of the extension study. Please see "[Methods](#Sec2){ref-type="sec"}" for important exceptions. *AE* adverse event, *CI* confidence interval, *DC* discontinuation, *HDL* high-density lipoprotein, *IR* incidence rate, *LDL* low density lipoprotein, *N/A* not available

In the extension study, small increases from baseline in ALC were observed at month 1 and month 3 in patients in the ADA to tofacitinib group; ALC levels returned to baseline at month 6 and were maintained through month 12. Small decreases from baseline in ALC were observed at all time points through month 12 in patients in the blinded to open-label tofacitinib group (Table [3](#Tab3){ref-type="table"}). In the extension study, patients in the ADA to tofacitinib group and patients in the blinded to open-label tofacitinib group had small increases from baseline in total cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL) and triglycerides at all time points through month 12 (except for LDL at month 3 in patients in the ADA to tofacitinib group) (Table [3](#Tab3){ref-type="table"}). At month 3 of the extension study, 2 patients (2 %) in the ADA to tofacitinib group and 4 patients (3 %) in the blinded to open-label tofacitinib group were receiving lipid-lowering agents.

Serious AEs occurring up to the month-3 visit of the extension study - that is, following the switch to tofacitinib - are presented in Table [4](#Tab4){ref-type="table"} alongside the action taken and patient outcomes. Two serious AEs resulted in death (lung malignancy, n = 1 (day 132); suicide, n = 1 (day 1); it is unknown whether the patient took the study drug on this day). One patient who developed vertigo during this period was still experiencing it 20 months later. All other patients who experienced a serious AE in the first 3 months of the extensions study recovered from the AE.Table 4Patient-level serious adverse events from switch to +3 monthsSerious AEDays after first tofacitinib dose in the extension studyAction taken (tofacitinib dosing)OutcomeADA 40 mg Q2W (blinded study) to tofacitinib 10 mg BID (extension study), N = 107Suicide (n = 1)1^a^Permanently withdrawnDeathOsteonecrosis (n = 1)23Temporarily withdrawnRecoveredPost-operative abscess (n = 1)44Dose not changedRecoveredInfectious peritonitis/appendicitis/intervertebral disc disorder (n = 1 each; same patient)44/46/51Permanently withdrawnRecoveredAutoimmune hepatitis (possible drug-induced liver injury; n = 1)55Permanently withdrawnRecoveredFractured ischium (n = 1)109Temporarily withdrawnRecoveringSpondylolisthesis/stenosis/lung malignancy (n = 1 each; same patient)117/117/132Not applicableDeath^b^Fractured femur (n = 1)134Temporarily withdrawnRecoveredTofacitinib 10 mg BID (blinded study) to tofacitinib 10 mg BID (extension study), N = 126Sinusitis (n = 1)13Permanently withdrawnRecoveredDyspnea/tendon rupture (n = 1 each; same patient)37/53Temporarily withdrawnRecoveredCervical dysplasia (n = 1)52Permanently withdrawnRecoveredMalignant melanoma (n = 1)85Permanently withdrawnRecoveredVertigo (n = 1)89Dose not changedNot recoveredDisseminated herpes simplex (n = 1)94Permanently withdrawnRecoveredCervical vertebral fracture/fall (n = 1 each; same patient)102/102Dose not changedRecoveringLung infiltration/atrial fibrillation (n = 1 each; same patient)^c^107/122Permanently withdrawnRecovered/not applicableGoiter (n = 1)120Temporarily withdrawnRecoveredIncludes patients who completed treatment with adalimumab (ADA) 40 mg every 2 weeks (Q2W) or tofacitinib 10 mg twice daily (BID) in the blinded study (or discontinued treatment for reasons other than a tofacitinib-related serious adverse event (AE)) and then enrolled in the extension study and switched treatment with minimal washout (≤2 weeks after their last dose of study drug in the blinded study). ^a^Unknown whether the patient took study drug on this day. ^b^Due to lung malignancy. ^c^Atrial fibrillation (day 122) occurred after drug discontinuation (day 107)

Efficacy {#Sec11}
--------

Greater proportions of patients had improvement in the signs and symptoms of RA, as measured by increased ACR response rates (Fig. [1](#Fig1){ref-type="fig"}) and reductions in mean DAS28-4(ESR), during the first 3 months of the extension study compared with the last 3 months of the blinded study in both the ADA to tofacitinib group and the blinded to open-label tofacitinib group (Fig. [2a](#Fig2){ref-type="fig"}). Of the 74 patients on ADA and 84 patients on tofacitinib who achieved an ACR20 response 3 months prior to switching in the double-blind study, 7 % (n = 5) and 7 % (n = 6), respectively, did not maintain an ACR20 response 3 months after switching to tofacitinib in the extension study.Fig. 1American College of Rheumatology (*ACR*) response rates 3 months before switch, at switch, and 3 months after switch\*. *ADA* adalimumab, *BID* twice daily. \*Includes patients who completed treatment with ADA 40 mg Q2W or tofacitinib 10 mg BID in ORAL Standard (or discontinued treatment for reasons other than a tofacitinib-related serious AE) and then enrolled in ORAL Sequel and switched treatment with minimal washout (≤2 weeks after their last dose of study drug in ORAL Standard). ACR, American College of Rheumatology; ACR20/50/70, 20/50/70% reduction in the number of tender and swollen joints, as well as 20/50/70% improvement in ≥3 of the other five ACR components; ADA, adalimumab; BID, twice daily; Q2W, every 2 weeksFig. 2Disease Activity Score for 28-joint counts based on the erythrocyte sedimentation rate (*DAS28-4(ESR*)) and changes from baseline in the Health Assessment Questionnaire-Disability Index (*HAQ-DI*) 3 months before switch, at switch, and 3 months after switch\*. *ADA* adalimumab, *BID* twice daily. \*Includes patients who completed treatment with ADA 40 mg Q2W or tofacitinib 10 mg BID in ORAL Standard (or discontinued treatment for reasons other than a tofacitinib-related serious AE) and then enrolled in ORAL Sequel and switched treatment with minimal washout (≤2 weeks after their last dose of study drug in ORAL Standard). Lower scores indicate less disease activity (DAS28--4\[ESR\]) or lower disability (HAQ-DI). ADA, adalimumab; BID, twice daily; DAS28--4(ESR), Disease Activity Score for 28 joint counts based on the erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire-Disability Index; Q2W, every 2 weeks; SE, standard error. (**a**) Changes from Baseline in Disease Activity Score for 28-joint counts based on Erythrocyte sedimentation rate (DAS28-4(ESR) 3 months before switch, at switch, and 3 months after switch.\* (**b**) Changes from Baseline in the Health Assessment QUestionnaire-Disability Index (HAQ-DI) 3 months before switch, at switch, and 3 months after switch\*

Similarly, further improvement in physical function, as measured by greater mean reductions in HAQ-DI score from baseline, was seen in both treatment groups (Fig. [2b](#Fig2){ref-type="fig"}).

Discussion {#Sec12}
==========

The clinical, functional, and radiographic efficacy and safety of tofacitinib 5 and 10 mg BID with and without MTX has been reported in patients with active RA in randomized phase 2 \[[@CR15]--[@CR19]\] and phase 3 studies \[[@CR7]--[@CR12]\]. The phase 3 study that included an ADA treatment arm demonstrated efficacy and safety results of tofacitinib consistent with the other phase 3 studies \[[@CR10]\]. The current analyses describe the safety and efficacy of open-label tofacitinib (with or without MTX) following a direct switch from blinded treatment with either ADA + MTX or tofacitinib + MTX.

Both proportions and exposure-adjusted incidence rates of DCs due to AEs, serious AEs, and serious infections over time were similar when switching from blinded ADA or tofacitinib to open-label tofacitinib. The increased incidence rates for these events in the initial 3 months of open-label tofacitinib, compared with the last 3 months of either blinded ADA or tofacitinib, suggests that these differences may be due to aspects of the study design inherent in the transition period rather than as a result of any overlapping immunomodulatory effects of ADA and tofacitinib. One potential explanation for the observed changes is the possibility of a measurement/detection effect. For example, the transition from the double-blind study to the open-label extension study may have driven an increase in patient/investigator sensitivity to reporting, whereby there was increased attribution of events in the extension study. Another limitation could have been the number of visits per 3-month period. Patients in the extension study had more frequent visits over the first 3 months of treatment (four visits) than they had in the final 3 months of the blinded study (two visits); thus, there were more opportunities to report an event in the first 3 months after the switch, which could have had an impact on the apparent incidence rate. Although a mechanistic or immunologic origin for the difference in safety profile cannot be ruled out, it is thought to be unlikely, as an increase was observed in both treatment sequences. On analysis of the proportions of patients experiencing TEAEs for 3 months before and 3 months after the switch, there was no clear pattern of changes during the switch. A further limitation is the potential change in dosing of permitted concomitant RA medications, including MTX, after switching.

Although the analyses of incidence rates per 100 patient-years of AEs in the blinded study included all patients regardless of whether they entered the extension, the data for the extension study included only those patients who completed the blinded study (that is, those who had data for the last 3 months of this study and who then enrolled in the extension). This introduces a potential censoring/truncation effect that is associated with identifying and analyzing a "completer" population. This effect may also apply to the efficacy response: patients with lesser efficacy responses may have been less likely to remain in the extension study to month 3, thereby, leading to seemingly greater improvements at month 3 among patients in this study. However, the incidence of both DCs and improvements in efficacy during the first 3 months of the extension study were similar between those patients who switched to ADA and those who continued to receive tofacitinib.

With these limitations in mind, we observed that switching directly from double-blind ADA 40 mg Q2W to open-label tofacitinib 10 mg BID resulted in sustained clinical response, with numeric improvements in all ACR response rates assessed, DAS28-4(ESR) scores, and mean change from baseline in HAQ-DI scores. Efficacy assessed at the same time points was similar in the double-blind tofacitinib 10 mg BID to open-label tofacitinib 10 mg BID group and the ADA to tofacitinib 10 mg BID group, and there was a similar pattern of increases in efficacy from the double-blind to the open-label extension.

One of the questions of interest was whether there are clinical consequences of potential overlapping immunomodulatory effects in the switch from ADA to tofacitinib. Analysis of AEs do not support such a conclusion but, in contrast, the contribution that overlapping pharmacologic exposure to ADA and tofacitinib makes to efficacy may be more difficult to assess. Although the first efficacy assessment at 3 months is well beyond the terminal half-life of the last dose of ADA \[[@CR20], [@CR21]\], pharmacodynamic effects may persist beyond what might be predicted from half-life/clearance data, and co-administered MTX reduces ADA clearance \[[@CR22]\]. Nevertheless, efficacy assessed at the same time points was similar in the tofacitinib to tofacitinib group and the ADA to tofacitinib group, with similar numeric patterns of improvement.

Conclusions {#Sec13}
===========

In summary, analysis of incidence rates of AEs showed a similar pattern over time for both ADA to tofacitinib and blinded to open-label tofacitinib treatment sequences in the year before and the year after switching, and there was no clear pattern of changes in TEAEs in the 3 months before and 3 months after the switch. Switching from both double-blind ADA and tofacitinib to open-label tofacitinib resulted in numeric improvements in signs and symptoms of disease and physical function. These results indicate that a patient's treatment can be directly switched from ADA to tofacitinib 10 mg BID, with a safety and efficacy profile similar to switching from blinded to open-label tofacitinib 10 mg BID. This analysis did not address potential differences between the safety profiles of ADA and tofacitinib in the phase 3 study for this cohort of patients, as this comparison is more appropriate in the primary safety analysis population \[[@CR10]\].
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